University of Colorado Boulder
↗Boulder, USA
The University of Colorado Boulder is a premier public R1 research university and the flagship institution of the University of Colorado system. It serves as a major hub for pharmaceutical and biotechnology innovation, particularly through its BioFrontiers Institute, which focuses on interdisciplinary bioscience research combining biology, engineering, and computer science. The university is a national leader in technology transfer, ranking #1 in the U.S. for startup launches in 2024.
CU Boulder specializes in translating basic research into clinical applications through its 'Venture Partners' arm. Key research areas include oncology, regenerative medicine, RNA-based therapeutics, and vaccine stability. While basic research occurs in Boulder, clinical translation is often executed in collaboration with the CU Anschutz Medical Campus and major regional health systems like UCHealth.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Translational Research & Spinoff Incubation
SIZE & FINANCIALS
Employees:10000+
Revenue:$1B-$5B (Total University Budget)
Founded:1876
Ownership:nonprofit
Status:operating
FUNDING
Total Raised:$742.2M (Annual Research Funding FY24)
Investors:National Institutes of Health (NIH), National Science Foundation (NSF), ARPA-H, NASA, Colorado Office of Economic Development (OEDIT)
PIPELINE
Stage:Discovery
Lead Drug Stage:Phase 2 (via Spinoffs)
Modalities:Small molecule, RNA therapeutics, Cell therapy, Peptides, Vaccines, CRISPR/Gene Editing
Active Trials:143
Trial Phases:Phase 1: 7 | Phase 2: 4 | Phase 4: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:University of Colorado System
Subsidiaries:BioFrontiers Institute, Venture Partners at CU Boulder, Center for Pharmaceutical Biotechnology
Key Partnerships:AstraZeneca (Oncology R&D collaboration), UCHealth (Clinical trial integration), Children's Hospital Colorado (Pediatric research), NIST (Biophysical characterization)
COMPETITION
Position:Leader
Competitors:Stanford University, MIT, University of California, San Diego, University of Michigan
LEADERSHIP
Key Executives:
Justin Schwartz - Chancellor
Massimo Ruzzene - Vice Chancellor for Research & Innovation
Bryn Rees - Associate Vice Chancellor for Innovation
Scientific Founders:Thomas Cech (Nobel Laureate, RNA research), Kristi Anseth (Regenerative Medicine), Leslie Leinwand (Cardiovascular/Metabolic research), Roy Parker (RNA biology/Oncology)
Board Members:Todd Saliman (CU System President), Callie Rennison (CU Regent), Nolbert Chavez (CU Regent)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with University of Colorado Boulder. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.